
DNTH Stock Forecast & Price Target
DNTH Analyst Ratings
Bulls say
Dianthus Therapeutics Inc. is positioned favorably due to its innovative focus on next-generation monoclonal antibodies for severe autoimmune and inflammatory diseases, which is supported by a competent executive team and an advancing clinical pipeline. The recent increase in price targets reflects improved net cash positions and a reduction in share count, enhancing the company's financial stability and growth prospects. Additionally, the licensing agreement with Nanjing Leads Biolabs for DNTH212 expands its development capabilities, underscoring the potential for broadening its therapeutic offerings and solidifying its market position.
Bears say
Dianthus Therapeutics Inc. is facing significant financial challenges, as its ability to advance its pipeline may be compromised if the company fails to secure sufficient funding. The removal of an assumed offering in fiscal year 2028 and the reduction of the fiscal year 2025 share count indicate a need for more cautious financial planning moving forward. These factors contribute to a negative outlook regarding the company's future operational capabilities and overall financial stability.
This aggregate rating is based on analysts' research of Magenta Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
DNTH Analyst Forecast & Price Prediction
Start investing in DNTH
Order type
Buy in
Order amount
Est. shares
0 shares